|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for YY1 |
 Gene summary |
| Basic gene Info. | Gene symbol | YY1 |
| Gene name | YY1 transcription factor | |
| Synonyms | DELTA|INO80S|NF-E1|UCRBP|YIN-YANG-1 | |
| Cytomap | UCSC genome browser: 14q | |
| Type of gene | protein-coding | |
| RefGenes | NM_003403.4, | |
| Description | INO80 complex subunit SYY-1Yin and Yang 1 proteindelta transcription factortranscriptional repressor protein YY1 | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 600013 | |
| HGNC : HGNC | ||
| HPRD : 02482 | ||
| Protein | UniProt: P25490 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_YY1 | |
| BioGPS: 7528 | ||
| Pathway | NCI Pathway Interaction Database: YY1 | |
| KEGG: YY1 | ||
| REACTOME: YY1 | ||
| Pathway Commons: YY1 | ||
| Context | iHOP: YY1 | |
| ligand binding site mutation search in PubMed: YY1 | ||
| UCL Cancer Institute: YY1 | ||
| Assigned class in mutLBSgeneDB | A: This gene has a literature evidence and it belongs to targetable_mutLBSgenes. | |
| References showing study about ligand binding site mutation for YY1. | 1. "Shi Z, Silveira A, Patel P, Feng X. YY1 is involved in RANKL-induced transcription of the tartrate-resistant acid phosphatase gene in osteoclast differentiation. Gene. 2004 Dec 8;343(1):117-26." 15563837 2. "Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther. 2007 Apr;6(4):1387-99." 17431117 | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0000122 | negative regulation of transcription from RNA polymerase II promoter | 9857059 |
| Top |
| Ligand binding site mutations for YY1 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | H316 | R314I | COAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for YY1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | H316 | R314I | -0.22866079 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for YY1 from PDB |
| Top |
| Differential gene expression and gene-gene network for YY1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for YY1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0027651 | Neoplasms | 7 | Biomarker |
| umls:C0019693 | HIV Infections | 3 | Biomarker, GeneticVariation |
| umls:C0242656 | Disease Progression | 1 | Biomarker |
| umls:C3714756 | Intellectual Disability | 1 | Biomarker |
| umls:C0007873 | Uterine Cervical Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for YY1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of YY1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | NUC | Nucleic Acids | 1ubd | C | H316 | ZN | ZINC(2+) | 1ubd | C | H316 |
| Top |
| Conservation information for LBS of YY1 |
| Multiple alignments for P25490 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |